Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s)

Joseph Carmicheal, Asish Patel, Vipin Dalal, Pranita Atri, Amaninder S. Dhaliwal, Uwe A. Wittel, Mokenge P. Malafa, Geoffrey Talmon, Benjamin J. Swanson, Shailender Singh, Maneesh Jain, Sukhwinder Kaur, Surinder K. Batra

Research output: Contribution to journalReview article

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an incredibly deadly disease with a 5-year survival rate of 9%. The presence of pancreatic cystic lesions (PCLs) confers an increased likelihood of future pancreatic cancer in patients placing them in a high-risk category. Discerning concurrent malignancy and risk of future PCL progression to cancer must be carefully and accurately determined to improve survival outcomes and avoid unnecessary morbidity of pancreatic resection. Unfortunately, current image-based guidelines are inadequate to distinguish benign from malignant lesions. There continues to be a need for accurate molecular and imaging biomarker(s) capable of identifying malignant PCLs and predicting the malignant potential of PCLs to enable risk stratification and effective intervention management. This review provides an update on the current status of biomarkers from pancreatic cystic fluid, pancreatic juice, and seromic molecular analyses and discusses the potential of radiomics for differentiating PCLs harboring cancer from those that do not.

Original languageEnglish (US)
Article number188318
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Volume1873
Issue number1
DOIs
StatePublished - Jan 2020

Fingerprint

Tumor Biomarkers
Pancreatic Neoplasms
Biomarkers
Pancreatic Juice
Neoplasms
Molecular Imaging
Adenocarcinoma
Survival Rate
Guidelines
Morbidity
Survival

Keywords

  • Biomarker
  • Early detection
  • IPMN
  • Pancreatic cancer
  • Pancreatic cystic lesions
  • Pancreatic ductal adenocarcinoma
  • Radiomics

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Elevating pancreatic cystic lesion stratification : Current and future pancreatic cancer biomarker(s). / Carmicheal, Joseph; Patel, Asish; Dalal, Vipin; Atri, Pranita; Dhaliwal, Amaninder S.; Wittel, Uwe A.; Malafa, Mokenge P.; Talmon, Geoffrey; Swanson, Benjamin J.; Singh, Shailender; Jain, Maneesh; Kaur, Sukhwinder; Batra, Surinder K.

In: Biochimica et Biophysica Acta - Reviews on Cancer, Vol. 1873, No. 1, 188318, 01.2020.

Research output: Contribution to journalReview article

@article{618e2584edac4c00ba3e19f340414c3a,
title = "Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s)",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) is an incredibly deadly disease with a 5-year survival rate of 9{\%}. The presence of pancreatic cystic lesions (PCLs) confers an increased likelihood of future pancreatic cancer in patients placing them in a high-risk category. Discerning concurrent malignancy and risk of future PCL progression to cancer must be carefully and accurately determined to improve survival outcomes and avoid unnecessary morbidity of pancreatic resection. Unfortunately, current image-based guidelines are inadequate to distinguish benign from malignant lesions. There continues to be a need for accurate molecular and imaging biomarker(s) capable of identifying malignant PCLs and predicting the malignant potential of PCLs to enable risk stratification and effective intervention management. This review provides an update on the current status of biomarkers from pancreatic cystic fluid, pancreatic juice, and seromic molecular analyses and discusses the potential of radiomics for differentiating PCLs harboring cancer from those that do not.",
keywords = "Biomarker, Early detection, IPMN, Pancreatic cancer, Pancreatic cystic lesions, Pancreatic ductal adenocarcinoma, Radiomics",
author = "Joseph Carmicheal and Asish Patel and Vipin Dalal and Pranita Atri and Dhaliwal, {Amaninder S.} and Wittel, {Uwe A.} and Malafa, {Mokenge P.} and Geoffrey Talmon and Swanson, {Benjamin J.} and Shailender Singh and Maneesh Jain and Sukhwinder Kaur and Batra, {Surinder K.}",
year = "2020",
month = "1",
doi = "10.1016/j.bbcan.2019.188318",
language = "English (US)",
volume = "1873",
journal = "Biochimica et Biophysica Acta - Reviews on Cancer",
issn = "0304-419X",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Elevating pancreatic cystic lesion stratification

T2 - Current and future pancreatic cancer biomarker(s)

AU - Carmicheal, Joseph

AU - Patel, Asish

AU - Dalal, Vipin

AU - Atri, Pranita

AU - Dhaliwal, Amaninder S.

AU - Wittel, Uwe A.

AU - Malafa, Mokenge P.

AU - Talmon, Geoffrey

AU - Swanson, Benjamin J.

AU - Singh, Shailender

AU - Jain, Maneesh

AU - Kaur, Sukhwinder

AU - Batra, Surinder K.

PY - 2020/1

Y1 - 2020/1

N2 - Pancreatic ductal adenocarcinoma (PDAC) is an incredibly deadly disease with a 5-year survival rate of 9%. The presence of pancreatic cystic lesions (PCLs) confers an increased likelihood of future pancreatic cancer in patients placing them in a high-risk category. Discerning concurrent malignancy and risk of future PCL progression to cancer must be carefully and accurately determined to improve survival outcomes and avoid unnecessary morbidity of pancreatic resection. Unfortunately, current image-based guidelines are inadequate to distinguish benign from malignant lesions. There continues to be a need for accurate molecular and imaging biomarker(s) capable of identifying malignant PCLs and predicting the malignant potential of PCLs to enable risk stratification and effective intervention management. This review provides an update on the current status of biomarkers from pancreatic cystic fluid, pancreatic juice, and seromic molecular analyses and discusses the potential of radiomics for differentiating PCLs harboring cancer from those that do not.

AB - Pancreatic ductal adenocarcinoma (PDAC) is an incredibly deadly disease with a 5-year survival rate of 9%. The presence of pancreatic cystic lesions (PCLs) confers an increased likelihood of future pancreatic cancer in patients placing them in a high-risk category. Discerning concurrent malignancy and risk of future PCL progression to cancer must be carefully and accurately determined to improve survival outcomes and avoid unnecessary morbidity of pancreatic resection. Unfortunately, current image-based guidelines are inadequate to distinguish benign from malignant lesions. There continues to be a need for accurate molecular and imaging biomarker(s) capable of identifying malignant PCLs and predicting the malignant potential of PCLs to enable risk stratification and effective intervention management. This review provides an update on the current status of biomarkers from pancreatic cystic fluid, pancreatic juice, and seromic molecular analyses and discusses the potential of radiomics for differentiating PCLs harboring cancer from those that do not.

KW - Biomarker

KW - Early detection

KW - IPMN

KW - Pancreatic cancer

KW - Pancreatic cystic lesions

KW - Pancreatic ductal adenocarcinoma

KW - Radiomics

UR - http://www.scopus.com/inward/record.url?scp=85074683964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074683964&partnerID=8YFLogxK

U2 - 10.1016/j.bbcan.2019.188318

DO - 10.1016/j.bbcan.2019.188318

M3 - Review article

C2 - 31676330

AN - SCOPUS:85074683964

VL - 1873

JO - Biochimica et Biophysica Acta - Reviews on Cancer

JF - Biochimica et Biophysica Acta - Reviews on Cancer

SN - 0304-419X

IS - 1

M1 - 188318

ER -